These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 27044768

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
    Di Bisceglie AM, Janczweska-Kazek E, Habersetzer F, Mazur W, Stanciu C, Carreno V, Tanasescu C, Flisiak R, Romero-Gomez M, Fich A, Bataille V, Toh ML, Hennequi M, Zerr P, Honnet G, Inchauspé G, Agathon D, Limacher JM, Wedemeyer H.
    Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484
    [Abstract] [Full Text] [Related]

  • 6. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
    Couzigou P, Pérusat S, Bourlière M, Trimoulet P, Poynard T, Leroy V, Marcellin P, Foucher J, Bronowicki JP, Chêne G, ANRS HC16 GAMMATRI Trial Group.
    J Gastroenterol Hepatol; 2013 Feb; 28(2):329-34. PubMed ID: 23190183
    [Abstract] [Full Text] [Related]

  • 7. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F, SMIEC II Investigators.
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the Safety Profiles of Pegylated Interferon α-2a and α-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study.
    Ide K, Sato I, Imai T, Hawke P, Yamada H, Kawasaki Y, Masaki N.
    Biol Pharm Bull; 2016 Dec 01; 39(12):2060-2065. PubMed ID: 27645378
    [Abstract] [Full Text] [Related]

  • 9. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.
    Caroleo B, Gallelli L, Staltari O, De Sarro G, Guadagnino V.
    Intervirology; 2008 Dec 01; 51(6):407-9. PubMed ID: 19258719
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Repeated Panniculitis Induced by Pegylated Interferon Alpha 2a in a Patient with Chronic Hepatitis C.
    Song JS, Sohn JH, Jeong JY, Min JH, Choi WS, Kim OZ, Pyo JY.
    Korean J Gastroenterol; 2016 May 25; 67(5):272-276. PubMed ID: 27206440
    [Abstract] [Full Text] [Related]

  • 13. [Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
    Cheong HR, Woo HY, Heo J, Yoon KT, Kim DU, Kim GH, Kang DH, Song GA, Cho M.
    Korean J Hepatol; 2010 Mar 25; 16(1):38-48. PubMed ID: 20375641
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.
    Minami T, Kishikawa T, Sato M, Tateishi R, Yoshida H, Koike K.
    J Gastroenterol; 2013 Feb 25; 48(2):254-68. PubMed ID: 22790350
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
    Dogan UB, Atabay A, Akin MS, Yalaki S.
    Eur J Gastroenterol Hepatol; 2013 Sep 25; 25(9):1082-5. PubMed ID: 23524524
    [Abstract] [Full Text] [Related]

  • 19. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN.
    J Gastroenterol Hepatol; 2007 May 25; 22(5):669-75. PubMed ID: 17444854
    [Abstract] [Full Text] [Related]

  • 20. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C.
    van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ, Schalm SW, Tan AC.
    Nephrol Dial Transplant; 2008 Feb 25; 23(2):721-5. PubMed ID: 18042614
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.